All In Biotech

Drug Trial Radar · NCT07871721

A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)

A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Phase 3b Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) on Clinical Response and Inhibition of Radiographic Progression in Participants With Active Psoriatic Arthritis

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 644 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

644

Planned (sponsor's estimate)

Start

Jan 11, 2027

Primary completion

Apr 18, 2030

Study completion Dec 30, 2030

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works and how safe it is in participants with active PsA who have not previously received biological medicines. The study will assess whether zasocitnib helps improve symptoms and slows or prevents further joint damage. Participants will have signs of inflammation in their blood and damage in at least two joints of their hands and feet. Participants will receive either zasocitinib or placebo during the first 24 weeks of the study. After week 24, all participants will receive zasocitinib through week 52. Participants will be in the study for up to 61 weeks.

Conditions

  • Psoriatic Arthritis

Interventions

  • PlaceboOther

    Zasocitinib matching placebo oral tablet.

  • ZasocitinibDrug

    Zasocitinib oral tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving an American College of Rheumatology (ACR) 20 Response at Week 24Time frame: At Week 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.